Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

h edema and occasionally serious fluid retention. Patients should be weighed and monitored regularly for signs and symptoms of fluid retention, which can be serious or life-threatening. Be advised to carefully investigate and provide appropriate management for unexpected weight gain. The probability of edema tended to be increased among older patients (>65 years) or those taking higher doses of GLEEVEC. If severe fluid retention occurs, GLEEVEC should be withheld until the event has resolved and then resumed depending on the initial severity of the event.

Cytopenias have been reported. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months). Dose reduction or treatment interruption may be required for severe neutropenia or thrombocytopenia (see full Prescribing Information for dose adjustment recommendations).

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of GLEEVEC. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment. If severe hepatotoxicity occurs, GLEEVEC should be withheld
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Hungary (PRWEB) April 30, 2015 ... lab notebook with integrated protocols and specimen management ... software solutions and consulting services for life science ... development of Labguru’s newest feature: chemical structure and ... domain features for biologists, bio-chemists, and more, the ...
(Date:4/30/2015)... MENLO PARK, Calif. , April 30, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... operating results on Thursday, May 7, 2015 after the ... host a conference call and webcast on Thursday, May ... Pacific to discuss the results and recent corporate developments. ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Fleur’s introduces CC ... the benefits of makeup, skin care and solar ... cream is designed with specific complexion-correcting pigments to ... complexion and a healthy glow. Far more than ...
(Date:4/30/2015)... Sunnyvale, California (PRWEB) April 30, 2015 ... the 2015 PharmaSUG Annual Conference held in ... Director of Staffing Solutions along with Leslie Kolman, Manager ... share the latest Clinovo news at Booth #17. ... PharmaSUG Annual Conference again this year”, Says Trisha Heredia, ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... NATICK, Mass., July 13 Boston Scientific ... for its LATITUDE(R) Patient Management system. The LATITUDE system ... on both the device and a patient,s heart health status. ... physician visits and send relevant data directly to a patient,s ...
... July 12 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: ... from the Nasdaq Global,Market ("Nasdaq"). , ... demand from existing and,potential international investors for the secondary ... the volume of Pharmaxis ADS trading,in the secondary Nasdaq ...
... Md., July 10 Martek Biosciences Corporation (Nasdaq: ... a conference call for investors to discuss DHA research recently ... will take place July 13, 2009, at approximately 9 a.m. ... call live via webcast by visiting Martek,s web site at ...
Cached Biology Technology:Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 2Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 3Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System 4Pharmaxis to Voluntarily De-List from Nasdaq 2
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... August 27, 2013 A recently reported blood test ... enable more timely therapeutic intervention in transplant patients and ... by scientists at the University Medical Center Gttingen and ... uses Bio-Rad Laboratories, Droplet Digital PCR (ddPCR) ...
... 2013) Fifteen years ago, a hematologist came to Dianna ... East Texas family suffered from a moderately severe bleeding disorder, ... surgery because they bled too much after surgery," said Milewicz, ... The University of Texas Health Science Center at Houston (UTHealth). ...
... The Gerontological Society of America (GSA) the ... aging has chosen Rozalyn M. Anderson, PhD, of ... the Nathan Shock New Investigator Award. The distinguished ... about aging through basic biological research. It was established ...
Cached Biology News:Researchers develop rapid, cost-effective early detection method for organ transplant injury 2Researchers develop rapid, cost-effective early detection method for organ transplant injury 3UTHealth, Swedish researchers uncover mystery in blot clotting disorder 2
... Have a novel target for which no ... Weve made custom antibodies for a variety of ... be happy to put our technology and expertise ... , Access to our patented RabMAb development technology ...
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... The ProteoSpin CBED Micro Kit provides a ... exchange and desalting of protein samples. The ... Norgens patented protein resin as an ion ... CaCl2,LiCl, CsCl have poor affinities for Norgens ...
... Endostatin. Canine Cytokine EIA Kits,(Competitive ... a line of enzyme-linked immunosorbent assay ... for multiple research applications. The line ... quick and dependable assays. The quantitative ...
Biology Products: